| abstract |
FIELD: pharmaceutics.SUBSTANCE: invention relates to the use of a drug that is an inhibitor of the interaction of HDM2 with p53, which is (S)-5-(5-chlorine-1-methyl-2-oxo-1,2-dihydropyridine-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1Н-pyrrolo[3,4-d]imidazole-4-one (HDM201), or its pharmacologically acceptable non-covalent derivative (including salt, solvate, hydrate, complex, co-crystal) for the treatment of hematological tumors, where the drug is injected on each of the first 6-8 days of a 28-day treatment cycle, where the treatment consists of at least two 28-day treatment cycles and where the daily dose of the drug is or is equivalent to 45 mg of free base of HDM201.EFFECT: technical result is that an effective treatment scheme for patients with hematological tumors is developed, where the drug is injected in accordance with the scheme of long-term injection of low doses.12 cl, 5 dwg, 7 tbl, 2 ex |